Table 4.
Observed Changes at M6 for Patients After Switching and Reasons for STR Discontinuation
| Clinical and biological parameters | N (%) |
|---|---|
| RPV/FTC/TDF improvment (N = 264)a | |
| Clinical tolerance improvement | 79 (29.9) |
| Neurological | 52 (19.7) |
| Patients previously on EFV | 41 (13.5) |
| Patients without EFV | 11 (4.2) |
| Digestive | 19 (7.2) |
| Other | 8 (3) |
| RPV/FTC/TDF discontinuation (N = 304) | 21 (6.9) |
| Virological failureb,c | 2 (0.7) |
| Tolerance | 16 (5.3) |
| Neurological disordersd | 8 (2.6) |
| Digestive disordersb | 7 (2.3) |
| Kidney disorderse | 2 (0.7) |
| Skin rash | 1 (0.3) |
| Nonadherence | 2 (0.7) |
| Pregnancy | 2 (0.7) |
Abbreviations: EFV, efavirenz; FTC, emtricitabine; RPV, rilpivirine; STR, single-tablet regimen; TDF, tenofovir disoproxil fumarate; STR, single-tablet regimen.
a 19 missing data plus 21 STR stop.
b 2 patients presented both neurological and digestive disorders.
c Discontinuation was proposed 3 and 8 months after switching for patients 1 and 2, respectively.
d 1 patient presented both virological failure and neurological disorder.
e 1 Fanconi syndrome and 1 excessive phosphate secretion in the urine.